Germany's Merck Scraps MS Drug Cladribine After Regulators' Rebuff
Merck KGaA ends development of oral cladribine tablets following rejection by European and U.S. regulators.
Merck KGaA ends development of oral cladribine tablets following rejection by European and U.S. regulators.